The Top 20 cancer therapy brands in Australia reached sales of about $545m in 2008, growing at a CAGR of 30% since 2005. Datamonitor forecasts this growth to slow down considerably to a CAGR of 5.6% between 2008 and 2018 mainly due to maturing markets and the entry of generics for several key products. Sales of the Top 20 brands are expected to reach a total of $940m in 2018.
Key reasons to purchase this title
- Identify key opportunities and threats that will impact the Australian oncology market as a whole and the Top 20 in particular
- Quantify the future size and scope of the Top 20 Australian cancer therapies market and predict the performance of its key compounds
- Understand critical success factors in growing and defending cancer brand franchises from new entrants and generics
